13th Japanese Safety Pharmacology Society Annual Meeting Program (as of January 20, 2022)
Online viewing period
- Live streaming period: February 4 (Fri) - 5 (Sat), 2022
- On-demand viewing period: February 4 (Fri) - March 18 (Fri), 2022
President: Atsushi Fujiwara (Ina Research Inc.)
Day 1: Friday, Feb. 4
| All day |
Poster Sessions <On-demand streaming> |
| 9:00 〜 |
Opening Atsushi Fujiwara (President of 13th Annual Meeting) |
| 9:10～10:55 |
Symposium I: Cardiovascular System <Live streaming>
- Current challenges and future perspectives of safety pharmacology testing using new approach methodologies
Yasunari Kanda (National Institute of Health Sciences)
- ICH S7B Q&A: Best practice for in vivo QT assay
Katsuyoshi Chiba (Daiichi Sankyo Co., Ltd.)
- ICH S7B Q&A: Best practice for in vitro assay
Takashi Yoshinaga (Eisai Co., Ltd.)
- Panel discussions
|
| 11:25 〜 12:25 |
Poster presentation <Live streaming> |
| 13:20 ～ 14:30 |
Sponsored Session 1<Live streaming>
- Zebrafish Role in Pharmacological Safety and Human Health Risks - New approaches for enhancing bio-pharmacological screening: from bench to bedside
Daniel Caballero-Díaz (ZeClinics) Ina Research Inc.
- Retrieving data from PharmaPendium in order to determine first-in-human doses
Takahiro Ohyama (Elsevier Japan K.K.) Elsevier Japan K.K.
|
| 15:00 〜 16:45 |
Symposium 2: Central Nervous System <Live streaming>
Cutting-edge drug dependence evaluation
- Present drug abuse situation in Japan
Tsutomu Suzuki (Department of Pharmacology, Faculty of Pharmacy, Shonan University of Medical Sciences)
- Evaluation of the adverse effects of new psychoactive substances: dependence and toxicity
Masahiko Funada (National Institute of Mental Health, National Center of Neurology and Psychiatry)
- Distress during the morphine withdrawal: Behavioral and cellular analysis
Tomohisa Mori (Department of Pharmacology, Hoshi University)
|
Day 2: Saturday, Feb. 5
| All day |
Poster Sessions <On-demand streaming> |
|
8:20～8:55
|
Sponsored Session 2 <Live streaming>
Human Cardiomyocytes and Spinal Cord Cultures for Cardiotoxicity and Neurotoxicity Risk Assessment
Najah ABI-GERGES (AnaBios Corporation) AnaBios Corporation |
| 9:05 ～ 10:25 |
Invited Lecture<Recorded presentation>
- To predict drug-induced cardiac toxicity by using weighted gene co-expression net-work analysis
Jufeng Wang (Pharmaron, Beijing, China）
- What we should include in study reports about how the QT interval is measured; precision, accuracy, or both
Brian Roche (Charles River Laboratories, Executive Director, Global Safety Pharmacology)
|
| 10:50-11:50 |
Poster presentation <Live streaming> |
| 12:20~13:30 |
Sponsored Session 3<Live streaming>
- ICH S1B(R1): ADDENDUM TO THE GUIDELINE ON TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS -- Suggestion of in vitro molecular targeted panel assay approach --
Masami Tamaoka, Makoto Imatachi (Eurofins Discovery, Japan) Eurofins Discovery, Japan
- MEA Measurement in Human Brain Organids ：Analysis using Low Frequency Componets
Ikuro Suzuki (Tohoku Institute of Technology) SCREEN Holdings Co., Ltd/Alpha MED Scientific Inc.
|
| 14:00～15:30 |
Workshop <Live streaming>
Safety pharmacology & SEND: Status and challenges
- Current Situation of SEND Conversion for Safety Pharmacology Studies
Shin-ichi Horikawa (Ina Research Inc.)
- Example of SEND Implementation in Pharmaceutical Company -Creation of SEND Datasets for Safety Pharmacology studies-
Izumi Matsumoto (Sumitomo Dainippon Pharma Co., Ltd.)
- Outsource the conversion of safety pharmacological tests to SEND
Fumio Masaki (CMIC Pharma Science Co., Ltd.)
|
| 16:00～16:40 |
Special Lecture <Live streaming>
- Uterus transplantation: from basic research toward future clinical application
Iori Kisu(Department of Obstetrics and Gynecology, Keio University School of Medicine)
|
| 16:40～ |
Closing <Live streaming>
Closing Remarks
- Atsushi Fujiwara (President of 13th Annual Meeting)
- Harushige Ozaki (President of 14th Annual Meeting)
|
